Literature DB >> 10504411

Characterization of recombinant and plant-derived mistletoe lectin and their B-chains.

J Eck1, M Langer, B Möckel, K Witthohn, H Zinke, H Lentzen.   

Abstract

Mistletoe lectin I (pML) and its isoforms ML II and III constitute the active principle in extract preparations from mistletoe, commonly used as immunomodulator in adjuvant tumour therapy. The heterodimeric disulfide-linked cytotoxic protein is classified as type II ribosome inactivating protein (RIP). Recently, the sequence coding for the mistletoe lectin prepro-protein was identified and the existence of a single intron-free gene was shown [Eck, J., Langer, M., Möckel, B., Baur, A., Rothe, M., Zinke, H. & Lentzen, H. (1999) Eur. J. Biochem. 264, 775-784]. The aim of this study was to prepare pure and homogeneous rMLB-chain as well as rML heterodimer for studying the carbohydrate binding specificity of recombinant versus natural protein and its contribution to the observed cytotoxic effect. Expression in E. coli resulted in the production of insoluble protein (inclusion bodies). A procedure for generating correctly folded, biochemically and biologically active rMLB was established starting from the insoluble single chain. Carbohydrate binding and specificity of pMLB and rMLB were analysed by a competitive enzyme linked lectin assay (ELLA). Asialofetuin was able to compete with binding of both chains (50% at 0.8 microM). The specificity of the B-chains to lactose was more distinct with halfmaximal competition at 4.9 mM (pMLB) and > 90 mM (rMLB), respectively. Furthermore, in a coassociation process rMLA- and rMLB inclusion bodies were associated in one step by defined dilution yielding active rML-heterodimer. The activities of recombinant (rML) and plant derived mistletoe lectin (pML) were compared. Cytotoxicity was determined using MOLT-4 cells and enzymatic rRNA N-glycosidase activity was measured in a coupled transcription/translation assay. The IC50 values of the two heterodimers were similar in both assays; rMLB-chain did not show any cytotoxic effect. In the ELLA with lactose as a competitor 50% competition of binding to asialofetuin was achieved at 1.6 mM (rML) and 1.8 mM (pML). Hence, using three different assays we found no significant differences between the recombinant protein and the glycosylated form of ML. Comparing the biological activities of the single chains with those of the heterodimer we conclude, that both, lectin activity and the rRNA N-glycosidase activity, are prerequisites for the cytotoxic effects on target cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504411     DOI: 10.1046/j.1432-1327.1999.00784.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  19 in total

1.  Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro.

Authors:  U Elsässer-Beile; M Voss; R Schühle; U Wetterauer
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Ricin and viscumin bind to different sites of the cell membrane.

Authors:  M M Moisenovich; I A Demina; I I Agapov; O V Chelnokova; N V Kozlovskaya; J Bereiter-Hahn; A G Tonevitsky; V I Shumakov
Journal:  Dokl Biol Sci       Date:  2002 Mar-Apr

3.  Pharmacokinetics of natural mistletoe lectins after subcutaneous injection.

Authors:  Roman Huber; Jürgen Eisenbraun; Barbara Miletzki; Michael Adler; Rainer Scheer; Reinhild Klein; Christoph H Gleiter
Journal:  Eur J Clin Pharmacol       Date:  2010-05-14       Impact factor: 2.953

4.  The identification of plant lectins with mucosal adjuvant activity.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; D T O'Hagan
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

Review 5.  [Mistletoe extract for treatment of urological tumors].

Authors:  H Suttmann; M Saar; C H Ohlmann; M Stöckle; J Kamradt
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

6.  Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.

Authors:  Gabriele Gamerith; Arno Amann; Bettina Schenk; Thomas Auer; Hans Lentzen; Dirk O Mügge; Katharina M Cima; Judith Löffler-Ragg; Wolfgang Hilbe; Heinz Zwierzina
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

7.  Mistletoe lectin I in complex with galactose and lactose reveals distinct sugar-binding properties.

Authors:  Ruth Mikeska; Roland Wacker; Raghuvir Arni; Tej P Singh; Albert Mikhailov; Azat Gabdoulkhakov; Wolfgang Voelter; Christian Betzel
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2004-12-24

8.  Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; O Leavy; E McNeela; K H G Mills; D T O'Hagan
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

9.  Unexpected different binding of mistletoe lectins from plant extracts to immobilized lactose and N-acetylgalactosamine.

Authors:  Tibor Hajtò; Fodor Krisztina; Aponyi Ildikò; Pallai Zsolt; Balogh Pèter; Németh Pèter; Perjési Pàl
Journal:  Anal Chem Insights       Date:  2007-09-17

10.  Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries.

Authors:  Imelda Lambkin; Clemencia Pinilla; Christa Hamashin; Lisa Spindler; Shannon Russell; Amy Schink; Rosa Moya-Castro; Gina Allicotti; Lisa Higgins; Melanie Smith; Jackie Dee; Carolyn Wilson; Richard Houghten; Daniel O'Mahony
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.